Recurrent and/or metastatic thyroid cancer: therapeutic options.
Thyroid cancer is relatively rare, accounting for 0.5 - 10 cases per 100,000 individuals per year. Despite their generally favourable prognosis, patients with differentiated thyroid cancer are at risk of tumour recurrence for decades after diagnosis. The optimal management remains controversial even...
المؤلفون الرئيسيون: | Karavitaki, N, Vlassopoulou, V, Tzanela, M, Tzavara, I, Thalassinos, N |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
2002
|
مواد مشابهة
-
Molecular staging using qualitative RT-PCR analysis detecting thyreoglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy.
حسب: Karavitaki, N, وآخرون
منشور في: (2005) -
Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome.
حسب: Tzanela, M, وآخرون
منشور في: (2004) -
Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion.
حسب: Tzanela, M, وآخرون
منشور في: (2005) -
Novel therapeutic options for recurrent metastatic salivary gland tumors: Review of ongoing clinical trials
حسب: Avinash Pandey, وآخرون
منشور في: (2018-01-01) -
THERAPEUTIC OPTIONS FOR INVASIVE BREAST CANCER
حسب: Ganusevich O. N., وآخرون
منشور في: (2019-05-01)